Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept.
Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors
/ adverse effects
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bevacizumab
/ administration & dosage
Camptothecin
/ adverse effects
Colorectal Neoplasms
/ drug therapy
Female
Fluorouracil
/ adverse effects
Humans
Kaplan-Meier Estimate
Leucovorin
/ adverse effects
Male
Middle Aged
Molecular Targeted Therapy
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Receptors, Vascular Endothelial Growth Factor
/ administration & dosage
Recombinant Fusion Proteins
/ administration & dosage
Retreatment
Treatment Outcome
Aflibercept
Bevacizumab
overall survival
tumor response
unresectable metastatic colorectal cancer
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
02
12
2020
accepted:
21
12
2020
entrez:
9
1
2021
pubmed:
10
1
2021
medline:
26
1
2021
Statut:
ppublish
Résumé
We compared the efficacy and safety of second-line FOLFIRI with bevacizumab (Bmab) or aflibercept (AFL) in patients with unresectable metastatic colorectal cancer (mCRC) to clarify selection criteria for anti-angiogenic agents. The subjects were patients with mCRC who received second-line FOLFIRI in combination with Bmab or AFL. The primary endpoint was median overall survival (OS). Secondary endpoints were median time to treatment failure (TTF), overall response rate (ORR) and incidence of adverse events. Data from 26 patients in the Bmab group and 19 in the AFL group were analyzed. Median OS was slightly longer in the AFL group compared to the Bmab group, whereas median TTF was similar. ORR tended to be higher in the AFL group. The incidence of ≥grade 2 diarrhea and proteinuria was significantly higher in the AFL group than the Bmab group. In patients given combination treatment with FOLFIRI for second-line treatment of mCRC, AFL can increase response rates compared to Bmab, which may contribute to longer survival.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
We compared the efficacy and safety of second-line FOLFIRI with bevacizumab (Bmab) or aflibercept (AFL) in patients with unresectable metastatic colorectal cancer (mCRC) to clarify selection criteria for anti-angiogenic agents.
PATIENTS AND METHODS
METHODS
The subjects were patients with mCRC who received second-line FOLFIRI in combination with Bmab or AFL. The primary endpoint was median overall survival (OS). Secondary endpoints were median time to treatment failure (TTF), overall response rate (ORR) and incidence of adverse events.
RESULTS
RESULTS
Data from 26 patients in the Bmab group and 19 in the AFL group were analyzed. Median OS was slightly longer in the AFL group compared to the Bmab group, whereas median TTF was similar. ORR tended to be higher in the AFL group. The incidence of ≥grade 2 diarrhea and proteinuria was significantly higher in the AFL group than the Bmab group.
CONCLUSION
CONCLUSIONS
In patients given combination treatment with FOLFIRI for second-line treatment of mCRC, AFL can increase response rates compared to Bmab, which may contribute to longer survival.
Identifiants
pubmed: 33419853
pii: 41/1/533
doi: 10.21873/anticanres.14805
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Antineoplastic Agents
0
Recombinant Fusion Proteins
0
aflibercept
15C2VL427D
Bevacizumab
2S9ZZM9Q9V
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Camptothecin
XT3Z54Z28A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
533-541Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.